ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 233 filers reported holding ROYALTY PHARMA PLC in Q3 2021. The put-call ratio across all filers is 0.36 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,882 | -0.1% | 253,610 | +13.1% | 0.56% | +1.8% |
| Q2 2023 | $6,892 | +25.1% | 224,220 | +46.6% | 0.56% | +18.6% |
| Q1 2023 | $5,510 | -12.8% | 152,930 | -4.4% | 0.47% | -15.4% |
| Q4 2022 | $6,319 | -99.9% | 159,915 | 0.0% | 0.55% | -4.5% |
| Q3 2022 | $6,425,000 | -4.4% | 159,915 | 0.0% | 0.58% | +2.5% |
| Q2 2022 | $6,722,000 | +7.9% | 159,915 | +0.0% | 0.56% | +29.3% |
| Q1 2022 | $6,229,000 | +7.6% | 159,895 | +10.1% | 0.44% | +6.8% |
| Q4 2021 | $5,787,000 | +72.5% | 145,235 | +56.4% | 0.41% | +56.1% |
| Q3 2021 | $3,355,000 | +33.6% | 92,850 | +51.6% | 0.26% | +33.7% |
| Q2 2021 | $2,511,000 | -2.0% | 61,260 | +4.3% | 0.20% | -9.3% |
| Q1 2021 | $2,562,000 | -11.2% | 58,740 | +1.9% | 0.22% | -16.3% |
| Q4 2020 | $2,885,000 | +120.2% | 57,640 | +85.0% | 0.26% | +96.9% |
| Q3 2020 | $1,310,000 | – | 31,150 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |